Education
About Us
Working with TipRanks
Follow Us
Tevogen Bio Holdings (TVGN)
NASDAQ:TVGN
TVGN Stock Chart & Stats
$0.32
-$0.17(-11.18%)
At close: 4:00 PM EST
$0.32
-$0.17(-11.18%)
Day’s Range― - ―
52-Week Range$0.14 - $1.51
Previous CloseN/A
Volume2.03M
Average Volume (3M)557.82K
Market Cap
$31.39M
Enterprise Value$37.75M
Total Cash (Recent Filing)$1.04M
Total Debt (Recent Filing)$7.53M
Price to Earnings (P/E)―
Beta0.40
Next Earnings
Jun 03, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.50
Shares Outstanding202,416,550
10 Day Avg. Volume531,944
30 Day Avg. Volume557,817
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-22.64
Price to Sales (P/S)0.00
P/FCF Ratio-12.59
Enterprise Value/Market Cap1.20
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-71.63
Enterprise Value/Ebitda-1.24
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-0.19
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary CTL PlatformTevogen’s proprietary off-the-shelf CD8+ cytotoxic T lymphocyte platform is a durable strategic asset. A validated platform can enable faster program expansion across oncology and infectious diseases, support scalable manufacturing and reduce per-product time-to-clinic, strengthening long-term competitive positioning.
Debt ReductionThe large reduction in debt materially lowers solvency and refinancing risk, improving financial flexibility. With less leverage the company has greater optionality to fund clinical programs or negotiate partnerships without high interest burdens, which supports longer-term program continuity.
Cash-earnings AlignmentFCF closely tracking net income indicates losses are cash-based rather than accounting distortions, improving predictability of cash burn. Transparent cash flow dynamics make planning financings and milestones more reliable, aiding management’s ability to sequence programs and allocate capital.
Bears Say
No RevenueThe absence of revenue means the business remains entirely pre-commercial and dependent on external funding. Persistent large net losses (TTM ≈ $30.8M) create a structural requirement for future financing, increasing dilution risk and making long-term program funding contingent on capital markets or partnerships.
Negative Equity & Small Asset BaseNegative stockholders’ equity and limited total assets limit balance-sheet resilience and borrowing capacity. This structural weakness constrains the company’s ability to raise secured financing, increases creditor scrutiny, and reduces margin for adverse clinical or funding setbacks over the medium term.
Rising Cash BurnPersistently negative operating cash flow and a sharp deterioration in free cash flow signal rising cash burn. Structurally higher expenditures without revenue heighten dependency on external capital, risking program delays or cuts if funding costs rise or markets tighten over the next several quarters.
Tevogen Bio Holdings News
TVGN FAQ
What was Tevogen Bio Holdings’s price range in the past 12 months?
Tevogen Bio Holdings lowest stock price was $0.14 and its highest was $1.51 in the past 12 months.
What is Tevogen Bio Holdings’s market cap?
Tevogen Bio Holdings’s market cap is $31.39M.
When is Tevogen Bio Holdings’s upcoming earnings report date?
Tevogen Bio Holdings’s upcoming earnings report date is Jun 03, 2026 which is in 88 days.
How were Tevogen Bio Holdings’s earnings last quarter?
Tevogen Bio Holdings released its earnings results on Nov 14, 2025. The company reported -$1.5 earnings per share for the quarter, beating the consensus estimate of -$3.04 by $1.54.
Is Tevogen Bio Holdings overvalued?
According to Wall Street analysts Tevogen Bio Holdings’s price is currently Overvalued.
Does Tevogen Bio Holdings pay dividends?
Tevogen Bio Holdings does not currently pay dividends.
What is Tevogen Bio Holdings’s EPS estimate?
Tevogen Bio Holdings’s EPS estimate is -2.
How many shares outstanding does Tevogen Bio Holdings have?
Tevogen Bio Holdings has 202,416,550 shares outstanding.
What happened to Tevogen Bio Holdings’s price movement after its last earnings report?
Tevogen Bio Holdings reported an EPS of -$1.5 in its last earnings report, beating expectations of -$3.04. Following the earnings report the stock price went down -6.081%.
Which hedge fund is a major shareholder of Tevogen Bio Holdings?
Currently, no hedge funds are holding shares in TVGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tevogen Bio Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 8.2%
Last 30 Days ▼ 8.2%
News Sentiment
Bearish
Bullish news 33%
Bearish news 67%
Bearish news 67%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-49.20%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
28.97%
Trailing 12-Months
Company Description
Tevogen Bio Holdings
Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.
TVGN Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Nkarta
―
C4 Therapeutics
―
Shattuck Labs
―
Nuvectis Pharma
―
Actuate Therapeutics, Inc.
―
Ownership Overview
69.32% Insiders
0.86% Mutual Funds
0.05% Other Institutional Investors
28.70% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---